Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$27.73
+0.83 (+3.09%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-34.7M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.4B
P/E
N/A
•EV/EBITDA
348.2x
↑ROE
-0.6%
↓Gross Margin
60.7%
↑Debt/Equity
0.06
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.6%
FCF CAGR
-76.8%
FCF margin
0.3%
FCF / Net income
-0.18x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $314.6M · net income $-4.5M · FCF $803349.7
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $314.6M | $314.6M | $278.6M | $292.4M | $283.3M |
| Net Income | $-4.5M | $-4.5M | $4.2M | $33.5M | $33.4M |
| EBITDA | $11.6M | $11.6M | $20.4M | $51.0M | $47.0M |
| EPS | -0.03 | -0.03 | 0.03 | 0.21 | 0.21 |
| Gross Margin | 60.7% | 60.7% | 69.7% | 68.6% | 67.5% |
| Operating Margin | -5.7% | -5.7% | -1.8% | 9.9% | 9.5% |
| Net Margin | -1.4% | -1.4% | 1.5% | 11.5% | 11.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.06 | 0.06 | 0.09 | 0.02 | 0.00 |
| Current Ratio | 6.85 | 6.85 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $803349.70 | $803349.70 | $-34.7M | $-51.4M | $64.3M |
| Returns | |||||
| ROE | -0.6% | -0.6% | 0.5% | 4.3% | 4.4% |
| Valuation | |||||
| P/E | — | — | 556.00 | 114.19 | 97.19 |
| EV/EBITDA | 348.19 | 348.19 | 109.42 | 72.77 | 65.30 |
| P/B | 5.53 | 5.53 | 3.03 | 4.93 | 4.28 |
| Growth & Yield | |||||
| Revenue Growth | 12.9% | 12.9% | -4.7% | 3.2% | — |
| EPS Growth | -200.0% | -200.0% | -85.7% | 0.0% | — |
| Dividend Yield | 0.2% | 0.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+78.7%
Start / end P/E
n/dx → n/dx
EPS bridge
0.03 → -0.03
Residual
+78.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.